GlobeNewswire·Nov 10, 2026, 7:00 AM ET

Olema Oncology Reports Third Quarter 2026 Financial and Operating Results

Olema Pharmaceuticals expects to announce top-line data from the Phase 3 OPERA-01 trial in the first quarter of 2027.
Enrollment continues to be strong for the Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136.
Jason O'Byrne was appointed as the new Chief Financial Officer.
The company ended the third quarter with $413.8 million in cash, cash equivalents, and marketable securities.
Net loss for the quarter ended September 30, 2026, was $73.6 million, compared to $42.2 million in the same period of 2025.
GAAP R&D expenses increased to $67.6 million, driven by patient enrollment in OPERA-01 and OPERA-02 trials and higher personnel costs.
GAAP G&A expenses rose to $9.9 million due to investments in personnel, infrastructure, and professional fees.
Upcoming events include presenting preclinical data on KAT6A at the EORTC-NCI-AACR Symposium in November 2026.
The company plans to present Phase 1b/2 data for OP-3136 and palazestrant combinations at the 2026 San Antonio Breast Cancer Symposium in December.
Enrollment will initiate in a Phase 1b/2 study for OP-3136 combined with darolutamide in the fourth quarter of 2026.
Palazestrant is currently evaluated as a monotherapy in OPERA-01 and in combination with ribociclib in OPERA-02.
OP-3136 is a KAT6 inhibitor currently advancing in Phase 1 studies across multiple indications.